• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DexCom Inc.

Dexcom Q4 earnings miss by a penny — but revenue up 23%

February 12, 2021 By Chris Newmarker

Dexcom updated logo

Dexcom (NSDQ:DXCM) reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections. The San Diego–based continuous glucose monitor company yesterday evening reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: CGM, Dexcom, DexCom Inc., Diabetes

Looking back at two decades of CGM advances

February 10, 2021 By Brian Buntz

FreeStyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), mHealth (Mobile Health) Tagged With: abbott, DexCom Inc., diabetes management, digital health, Eversense, FDA, Medtronic, mhealth, Senseonics

Lilly to integrate DexCom CGMs in automated dosing system

December 16, 2019 By Sean Whooley

Eli Lilly (NYSE:LLY) announced that it will integrate Dexcom (NSDQ:DXCM) products into its personalized diabetes management system, now under development. Under the new, non-exclusive agreement, Indianapolis-based Lilly will use San Diego-based Dexcom’s continuous glucose monitoring (CGM) devices in pen-based and pump-based platforms in Lily’s diabetes management system. The pen-based platform is designed to integrate personalized data from […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Dexcom, DexCom Inc., Eli Lilly & Co., elililly

FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller

December 13, 2019 By Nancy Crotti

Tandem Diabetes Care t:slim 2 Control-IQ artificial pancreas

The FDA today cleared the Tandem Diabetes Care (NSDQ:TNDM)  t:slim X2 insulin pump and Control-IQ advanced hybrid closed-loop technology to control Type 1 diabetes. The agency also granted De Novo clearance to the Control-IQ device, which is compatible with a variety of continuous glucose monitors and insulin pumps. The t:slim system, which also includes the recently […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA) Tagged With: artificialpancreas, DexCom Inc., FDA, Tandem Diabetes Care

Dexcom warns of potential danger to European app users

December 9, 2019 By Nancy Crotti

Dexcom updated logo

Dexcom (NSDQ:DXCM) is warning European customers who have failed to updated the G6 iOS app for their G6 continuous glucose monitor that they may not receive scheduled alerts of high or low blood sugar. Failure to update to version 1.5.4 of the app may cause alarms and alerts from the G6 continuous glucose monitor to […]

Filed Under: Diabetes, Featured, Patient Monitoring Tagged With: DexCom Inc.

Dexcom wins FDA clearance for G6 Pro CGM

October 8, 2019 By Brad Perriello

Dexcom updated logo

Dexcom (NSDQ:DXCM) said today that it won 510(k) clearance from the FDA for its G6 Pro continuous glucose Monitor for diabetic patients ages ages two years and up. The San Diego-based company said the G6 Pro is designed to measure glucose data in real time over 10 days in either “blinded” or “unblinded mode,” depending on […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: DexCom Inc.

Report: Dexcom shares drop in response to ‘headwinds’ comment

September 9, 2019 By Nancy Crotti

Dexcom updated logo

Shares in Dexcom (NSDQ:DXCM) dropped nearly 6.8% this morning following comments by a company executive that the company is facing “headwinds” that could hamper third-quarter results, according to a report by SeekingAlpha. EVP and CFO Quentin Blakford told attendees at Morgan Stanley’s Healthcare Conference in New York that comparisons to Q3 2018 results could be […]

Filed Under: Business/Financial News, Diabetes, Featured, Uncategorized, Wall Street Beat Tagged With: DexCom Inc.

Dexcom claims win in patent war with AgaMatrix unit WaveForm

August 26, 2019 By Brad Perriello

Dexcom, AgaMatrix

Dexcom Inc. (NSDQ:DXCM) last week claimed a win along one front of its patent war with AgaMatrix subsidiary WaveForm Technologies, when an Oregon federal court dismissed a lawsuit alleging that its continuous glucose monitors infringe WaveForm patents. Wilsonville, Ore.-based WaveForm sued Dexcom in March 2016, alleging infringement of a trio of patents covering a compound […]

Filed Under: Diabetes, Featured, Legal News Tagged With: agamatrix, DexCom Inc., waveformtechnologies

Dexcom posts Street-beating Q2 earnings

July 31, 2019 By Chris Newmarker

Dexcom updated logo

Dexcom (NSDQ:DXCM) posted second-quarter results this evening that beat the consensus forecast on Wall Street, and raised its outlook for the rest of the year. The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or $0.12 per share, on sales of $336.4 million for the three months ended June 30. […]

Filed Under: Business/Financial News, Diabetes, Featured, Wall Street Beat Tagged With: DexCom Inc.

Dexcom plans Apple Watch CGM launch

June 17, 2019 By Danielle Kirsh

Dexcom updated logo

Dexcom Inc. (NSDQ:DXCM) is launching upgrades for its G6 diabetes system and plans to launch its direct-to-Apple Watch version over the next year. The Apple and Dexcom collaboration would allow diabetes patients to track glucose through the Apple Watch, a consumer wearable, according to CNBC. “It’s coming,” Dexcom CEO Kevin Sayer told the network. “And […]

Filed Under: Diabetes Tagged With: DexCom Inc.

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS